Talazoparib plus enzalutamide in men with HRR-deficient metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial

Journal:
The Lancet
Published:
Affiliations:
25
Authors:
20
Institutions Authors Share
Pfizer, United States of America (USA)
4.000000
0.20
National Center for Tumor Diseases (NCT) Heidelberg, Germany
1.000000
0.05
National Cancer Center (NCC), South Korea
1.000000
0.05
IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Italy
1.000000
0.05
Peter MacCallum Cancer Centre (Peter Mac), Australia
1.000000
0.05
Pontifical Catholic University of Rio Grande do Sul (PUCRS), Brazil
1.000000
0.05
Vall d'Hebron University Hospital (HUVH), ICS, Spain
1.000000
0.05
Huntsman Cancer Institute at the University of Utah (HCI), Utah, United States of America (USA)
1.000000
0.05
Fudan University Shanghai Cancer Center (FUSCC), China
1.000000
0.05
National Cancer Center Hospital East, Japan
1.000000
0.05
Arizona Urology Specialists, United States of America (USA)
1.000000
0.05
START Carolinas, United States of America (USA)
1.000000
0.05
UiO Akershus University Hospital (Ahus), Norway
1.000000
0.05
Auckland City Hospital (ACH), New Zealand
0.500000
0.03
Institute Gustave-Roussy (IGR), France
0.500000
0.03
Centre Oscar Lambret, France
0.500000
0.03
University of Glasgow, United Kingdom (UK)
0.500000
0.03
Beatson West of Scotland Cancer Centre (BWoSCC), United Kingdom (UK)
0.500000
0.03
The University of Auckland, New Zealand
0.500000
0.03
Victor Hugo Clinic, France
0.500000
0.03
Centre Jean Bernard, France
0.500000
0.03